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GRAPHICAL ABSTRACTBackground: Atopic eczema (AE) is characterized by skin
barrier and immune dysfunction. Null mutations in filaggrin
(FLG), a key epidermal barrier protein, strongly predispose to
AE; however, the precise role of FLG deficiency in AE
pathogenesis remains incompletely understood.
Objectives: We sought to identify global proteomic changes
downstream of FLG deficiency in human epidermal living skin–
equivalent (LSE) models and validate findings in skin of patients
with AE.
Methods: Differentially expressed proteins from paired control
(nontargeting control short hairpin RNA [shNT]) and FLG
knockdown (FLG knockdown short hairpin RNA [shFLG])
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Results: Proteomic analysis identified 17 (P <_ .05)
differentially expressed proteins after FLG knockdown,
including kallikrein-7 (KLK7; 2.2-fold), cyclophilin A
(PPIA; 0.9-fold), and cofilin-1 (CFL1, 1.3-fold). Differential
protein expression was confirmed in shNT/shFLG LSEs;
however, only KLK7 was transcriptionally dysregulated.
Molecular pathways overrepresented after FLG
knockdown included inflammation, protease activity, cell
structure, and stress. Furthermore, KLK7 (1.8-fold)
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Abbreviations used
AE: Atopic eczema
ANXA3: Annexin A3
CFL1: Cofilin-1
CTSV: Cathepsin V
eIF: Eukaryotic initiation factor
FLG: Filaggrin
IPA: Ingenuity Pathway Analysis
KLK7: Kallikrein-7
LSE: Living skin equivalent
mTOR: Mammalian target of rapamycin
PPIA: Cyclophilin A
RT-qPCR: Quantitative RT-PCR
shNT: Nontargeting control short hairpin RNA
shFLG: Filaggrin knockdown short hairpin RNA
TXN: Thioredoxin
VIM: Vimentin
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2 ELIAS ET ALlesional biopsy specimens from patients with AE relative to
normal skin.
Conclusions: For the first time, we show that loss of FLG in the
absence of inflammation is sufficient to alter the expression level
of proteins relevant to the pathogenesis of AE. These include
proteins regulating inflammatory, proteolytic, and cytoskeletal
functions. We identify PPIA as a novel protein with levels that
are decreased in clinically active AE skin and show that the
characteristic upregulation of KLK7 expression in patients with
AE occurs downstream of FLG loss. Importantly, we highlight
disconnect between the epidermal proteome and transcriptome,
emphasizing the utility of global proteomic studies. (J Allergy
Clin Immunol 2017;nnn:nnn-nnn.)
Key words: Atopic eczema, dermatitis, skin, proteomic, filaggrin,
kallikrein-7, cyclophilin A
Filaggrin (FLG) is a major constituent of the epidermal barrier,
contributing to its structure, function, and hydration.1 Both sin-
gle- and double-allele loss-of-function mutations in FLG strongly
predispose to the development of atopic eczema (AE) and second-
ary atopic conditions, including asthma and allergic rhinitis.2-4 To
date, more than 40 different population-specific FLG mutations
have been identified, each resulting in a truncated profilaggrin
gene product, which is not processed into functional FLG mono-
mers.3 Up to 50% of cases of moderate-to-severe AE in northern
Europe can be attributed, at least in part, to an FLG-null muta-
tion,5,6 representing the strongest and most consistent genetic
risk factors identified for AE to date (overall odds ratio, 3.12-
4.78).6,7 Furthermore, FLG is polymorphic, with common allelic
variants encoding a profilaggrin molecule composed of 10, 11, or
12 FLGmonomeric repeats. Each additional FLG repeat confers a
reduced risk of AE by a factor of 0.88, suggesting that even small
increases in FLG expression might be therapeutically beneficial.8
Both the flaky tail mouse (which carries a natural mutation
virtually ablating all FLG expression9) and FLG knockout mice
exhibit enhanced percutaneous antigen transfer and allergen/
irritant-induced AE-like inflammatory responses.10,11 These
models support a primary role for FLG and highlight the impor-
tance of a functional cutaneous barrier in AE disease pathogenesis.
Recent cohort studies have examined global gene expression
changes in patients with AE stratified by FLG genotype.12,13
Although interesting, their interpretation with regard to the direct
role of FLG in AE pathogenesis is confounded by the complex
interplay between the epidermal barrier, immune system, and envi-
ronment.14 For example, loss of FLG is also observed in patients
with FLG wild-type AE, likely because of its extrinsic downregu-
lation by the atopic TH2-polarized microenvironment.
15Moreover,
murine models are additionally limited both by secondary muta-
tions, notably null mutations in TMEM79/Matt (Mattrin) in the
flaky tail mouse,16 and interspecies differences. The human and
murine FLG sequences lack homology,17 and murine models do
not display the heterozygote phenotype typical of most patients
with AE.10,11 Consequently, the precise molecular changes occur-
ring directly as a result of FLG loss are relatively unknown.
A useful alternative tool for the study of epidermal biology is
the 3-dimensional living skin–equivalent (LSE) model derived
exclusively from primary human keratinocytes. Although by
definition these simplified models do not recapitulate the
complexity of human AE skin, they enable the study of epidermalbiology in the absence of confounding inflammatory cells.18
Furthermore, they enable the effect of FLG gene silencing to be
analyzed in a pairwise manner on a homogeneous genetic
background.
Previous LSE studies have largely focused on understanding
the ultrastructural and functional consequence of FLG defi-
ciency.19-21 In many regards these mirror changes observed in
AE skin, supporting their utility as a disease model. However,
to the best of our knowledge, no systematic transcriptomic or pro-
teomic analysis has been performed after FLG knockdown in hu-
man epidermis. The aim of this study was to use FLG knockdown
LSE models to investigate the global molecular consequences re-
sulting directly from FLG deficiency. A proteomics-based
approach was used because protein changes largely represent
the functional end point of cell signaling, and recent studies
have identified an important disconnect between the transcrip-
tome and proteome, suggesting that significant posttranscrip-
tional regulation occurs.22
Notably, for the first time, we have identified 17 proteins that
are significantly differentially expressed after FLG knockdown
in LSE cultures. Bioinformatic analysis was used to categorize
and align these to putative regulatory networks and showed that
loss of FLG alone is sufficient to induce protein changes
relevant to the pathogenesis of AE. Specifically, pathways
relating to protease activity, inflammation, cell structure, and
stress were overrepresented after FLG knockdown. The expres-
sion profile of key targets, namely the AE-relevant protease
kallikrein-7 (KLK7), the novel AE immune modulator cyclo-
philin A (PPIA), and the actin-binding protein cofilin-1
(CFL1), were replicated first in independent FLG knockdown
LSEs and then further characterized in skin biopsy specimens
from patients with AE.METHODS
Primary keratinocyte culture
Normal human epidermal keratinocytes extracted from surplus foreskin
tissue obtained after informed biobank consent were cultured in low-calcium
(0.06 mmol/L) EpiLife supplemented with 1% human keratinocyte growth
supplement (Life Technologies, Paisley, United Kingdom), as previously
described.23 All donor subjects had no history of AE.
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transduction of primary keratinocytes
Lentivirus production from GIPZ lentiviral shRNAmir vectors (Open
Biosystems, Lafayette, Colo) targeting FLG (filaggrin knockdown short
hairpin RNA [shFLG], V3LHS_369921) or a nontargeting control sequence
(nontargeting control short hairpin RNA [shNT], RHS4346) and keratinocyte
transduction were performed, as previously described.24 Further details are
provided in the Methods section in this article’s Online Repository at www.
jacionline.org.LSE culture and protein extraction
LSEs were generated from independent biological donors (n 5 10 for
proteomic analysis and a further n 5 3-8 for validation experiments) and
proteins extracted in 8 mol/L urea lysis buffer, as previously described.24
Further details are provided in this article’s Online Repository.Patient samples
Patients with AE (as diagnosed per the United Kingdom–modified Hanifin
and Rajka criteria25) were recruited from a tertiary referral dermatology clinic.
Patients older than 18 years not receiving systemic immune-modifying drugs
were included in the study after written informed consent and a 2-week
washout period from potent topical steroids. Five-millimeter punch biopsy
specimens were taken from both lesional and nonlesional skin after achieve-
ment of local anesthesia. After obtaining informed consent, normal (control)
skin was collected after plastic surgery or excision of benign cutaneous le-
sions. A blood samplewas also collected from all patients and control subjects
for FLG mutational analysis (further details provided in this article’s Online
Repository). All control subjects reported in the study had no history of AE
and were FLG wild-type. This study was approved by the Regional Research
Ethics Committee and was conducted according to the Declaration of Helsinki
principles.Immunoblotting and densitometry
Immunoblotting was performed by using standard protocols, as previously
described.24 Primary antibody conditions were as follows: FLG clone 15C10
(1:200; NCL-FLG; Leica Biosystems, Newcastle upon Tyne, United
Kingdom), CFL1 (1:500; PA5-27627, Thermo Scientific, Waltham, Mass),
KLK7 (1:1000; AF2624; R&D Systems, Minneapolis, Minn), PPIA (1:300;
39-1100; Life Technologies), and glyceraldehyde-3-phosphate dehydroge-
nase (1:10,000; #2118; Cell Signaling Technology, Danvers, Mass). Further
details are provided in this article’s Online Repository.Proteomic and data analysis
Proteins were prepared by means of in-solution or in-gel digestion and
subjected to liquid chromatography/mass spectrometry proteomic analysis.
Data analysis was performed with Proteome Discoverer (Thermo Fisher
Scientific) and Scaffold (Proteome Software, Portland, Ore). Protein identi-
fications were accepted if they could be established at greater than 99.9%
probability and contained at least 2 identified peptides. Further details are
provided in this article’s Online Repository.Immunofluorescence
OCT-embedded LSE and skin cryosections (4 mm) were fixed and stained,
as previously described.24 Primary antibody conditions were as follows: FLG
(Acetone fix, 1:100; MS-449-P1; Thermo Scientific), CFL1 (paraformalde-
hyde fix, 1:300; PA5-27627; Thermo Scientific), KLK7 (Methanol fix,
1:250; AF2624; R&D Systems), and PPIA (paraformaldehyde fix, 1:500;
39-1100; Life Technologies). Quantification was performed with ImageJ soft-
ware (National Institutes of Health, Bethesda, Md). Further details are pro-
vided in this article’s Online Repository.Quantitative RT-PCR
Quantitative RT-PCR (RT-qPCR) was performed, as described by Forrester
et al,24 with exon-spanning probe-based assays: FLG (Hs.PT.53a.23095403,
FAM/TAMRA; Integrated DNA Technologies, Coralville, Iowa), PPIA (for-
ward: ATGCTGGACCCAACACAAAT; reverse: TCTTTCACTTTGCC
AAACACC; UPL PROBE#48 FAM/NFQ; Roche, Mannheim, Germany),
CFL1 (forward: GTGCCCTCTCCTTTTCGTTT; reverse: TTGAACACCTT
GATGACACCAT; UPL PROBE#5 FAM/NFQ; Roche), and KLK7
(Hs.PT.58.39819237, FAM/TAMRA; Integrated DNA Technologies). 18S
was used as a housekeeping gene for normalization purposes.26 Further details
are provided in this article’s Online Repository.Statistical analysis
Unless otherwise stated in the figure legends, data points represent
means 6 95% CIs. Statistical analysis was performed with Prism 5 software
(GraphPad Software, La Jolla, Calif). Further details are provided in this
article’s Online Repository.RESULTS
Establishment of an FLG-deficient human LSE
model
Reliable and reproducible knockdown of FLG expression in
primary keratinocytes was achieved by using a second-generation
pGIPZ lentiviral shRNAmir construct targeting the FLG mRNA
sequence (shFLG). A nontargeting shRNAmir construct was
used as a control (shNT). LSEs were established from transduced
keratinocytes, and protein and mRNA knockdown was assessed at
day 14 of culture, the time point at which LSEs are fully differen-
tiated (Fig 1 and see Fig E1 in this article’s Online Repository at
www.jacionline.org). Densitometry of immunoblots confirmed
significant knockdown in both profilaggrin (75% 6 4.1%,
P <_ .0001) and FLG (79% 6 3.1%, P <_ .0001) proteins (Fig 1,
A, B, and D). RT-qPCR confirmed a significant reduction in
FLG mRNA expression (69% 6 4.9%, P <_ .0001; Fig 1, E). His-
tologic examination of LSE sections showed no overt phenotypic
changes between nonvirally modified LSEs and the shNT control
LSEs (data not shown) or between the shNTand shFLG LSEs (Fig
1,C). However, quantification with ImageJ analysis software iden-
tified a small but significant increase in epidermal thickness after
FLG knockdown compared with the shNT control. As such, both a
thicker viable cell layer (1.146 0.03-fold, P5 .0007) and stratum
corneum (1.136 0.06-fold, P5 .05) were observed (see Fig E2 in
this article’s Online Repository at www.jacionline.org).Seventeen proteins were significantly differentially
regulated after FLG knockdown in human
epidermal skin equivalent
The soluble protein fraction from paired shNTand shFLG LSE
samples generated from 10 independent biological human donors
displaying normal patterns of baseline FLG expression (see Fig
E3 in this article’s Online Repository at www.jacionline.org)
were subject to an open proteomic workflow (Fig 2, A). One thou-
sand six hundred forty unique proteins were identified across all
samples, with an average of 634 proteins identified per LSE. Of
these, 367 proteins were identified in at least 75% of the shNT
and shFLG paired samples (see Table E1 in this article’s Online
Repository at www.jacionline.org). The unweighted spectrum
counts from this subset of proteins were used in subsequent
FIG 1. Generation of shFLG and shNT LSE models. A and B, Representative FLG immunoblot (n5 11; Fig 1,
A) and immunofluorescence (2150 mm, n 5 3; Fig 1, B).MW, Molecular weight. C, Hematoxylin and eosin–
stained LSE morphology (2100 mm, n 5 10). D and E, Normalized FLG densitometry of immunoblots
(n 5 11; Fig 1, D) and TaqMan mRNA expression levels (n 5 8; Fig 1, E). Scatter plots of log10-transformed
data (means 6 95% CIs).
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logical donor and not FLG status (see Fig E4 in this article’s On-
line Repository at www.jacionline.org). To account for the
prominent donor effect, log10 differences between shNT and
shFLG conditions were calculated for each biological donor (ie,
a paired design), and log10 estimated differences in expression
profile were used for input for statistical analysis. A summary
of the differential expression profile for each biological donor is
represented as a heat map (see Fig E5 in this article’s Online Re-
pository at www.jacionline.org). Overlaid dendrogram plots de-
pict clustering between protein response profiles.
Notwithstanding the prominent intradonor variability, statisti-
cal analysis of the combined data set identified 17 differentially
regulated proteins (P <_.05; Fig 3 and see Table E2 in this article’s
Online Repository at www.jacionline.org). Positive/negative
mean differences represent upregulated/downregulated proteins
after FLG knockdown, respectively. Differentially expressedproteins broadly relate to a range of functional classes, including
proteases (KLK7, cathepsin V [CTSV], and carboxypeptidase A4
[CPA4]), inflammatory mediators (annexin A3 [ANXA3],
lymphocyte antigen 6D [LY6D], PPIA, and thioredoxin
[TXN]), and cytoskeletal interactors (FLG, vimentin [VIM],
CFL1, T-complex protein 1 subunit zeta [CCT6A], and tripartite
motif-containing protein 29 [TRIM29]). The most significantly
downregulated protein was FLG (P 5 2.0E-04), internally vali-
dating the analysis methodology.FLG-deficient LSEs display expression changes
consistent with inflammatory dermatoses
Ingenuity Pathway Analysis (IPA) identified ‘‘immunological
disease’’ (P5 2.14E-06 to 3.58E-02, 9 proteins), ‘‘dermatological
disease’’ (P5 2.42E-05 to 3.99E-02, 6 proteins), and ‘‘inflamma-
tory disease’’ (P5 2.42E-05 to 3.66E-03, 7 proteins; Fig 4, A, and
FIG 2. Overview of the open proteomic workflow. Peptides were extracted from shNT and shFLG LSEs and
separated by means of liquid chromatography mass spectrometry (LC-MS and LC-MS/MS). Proteins were
identified from MS/MS spectra, and unweighted spectrum counts were used to determine relative expres-
sion levels. Selected targets were independently validated.
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
ELIAS ET AL 5see Table E3 in this article’s Online Repository at www.
jacionline.org) as the categories most significantly associated
with FLG knockdown. Interestingly, within these categories, the
most significantly associated functional term was ‘‘allergy’’
(P 5 2.15E-06, 6 proteins). A detailed breakdown of the func-
tional terms underlying the top 5 associated disease categories
is included in Table E4 in this article’s Online Repository at
www.jacionline.org.FLG knockdown in LSEs leads to enrichment in
proteins associated with cellular assembly
Further IPA analysis identified that the ‘‘molecular and cellular
functions’’ most significantly overrepresented in our data set were
‘‘cellular movement’’ (P 5 3.05E-04 to 4.96E-02, 7 proteins),
‘‘cellular development’’ (P 5 3.94E-04 to 4.47E-02, 7 proteins),
and ‘‘cell growth and proliferation’’ (P5 3.94E-04 to 4.47E-02, 6
proteins; Fig 4, B, and see Table E5 in this article’s Online Repos-
itory at www.jacionline.org). Significant functional terms
included ‘‘migration of cells’’ (P 5 3.06E-03, 7 proteins) and
‘‘differentiation of cells’’ (P5 2.94E-02, 6 proteins). Full details
of the functional terms associated with the top 5 cellular function
categories are provided in Table E4.
Network analysis returned a single putative network linking all
of the differentially regulated proteins with an IPA p-score of 45
(p-score 5 2log10 [P value], see Fig E6 in this article’s Online
Repository at www.jacionline.org). Consistent with the previous
analysis, significant functional terms associated with the network
included ‘‘hyperplasia of epithelial cells’’ (P 5 1.02E-06, 7 pro-
teins) and ‘‘formation of skin’’ (P5 3.69E-06, 12 proteins). Pro-
teins implicated in dermatological and/or inflammatory disease
have been highlighted in pink (see Fig E6).Proteins involved in cell stress signaling pathways
are overrepresented in LSEs after FLG knockdown
The canonical pathways most significantly associated with the
differentially expressed proteins included ‘‘EIF2 signaling’’
(P 5 1.51E-05, 4 proteins), ‘‘regulation of eukaryotic initiation
factor (eIF) 4 and p70S6K signaling’’ (P5 1.40E-03, 2 proteins),
and ‘‘mammalian target of rapamycin (mTOR) signaling’’
(P 5 1.08E-02, 2 proteins; Fig 4, C, and see Table E6 in this ar-
ticle’s Online Repository at www.jacionline.org). The top 5
significantly associated canonical pathways are also overlaid
onto the putative molecular network (see Fig E6).Confirmation of proteomics results in independent
LSEs
A number of differentially expressed proteins were selected for
independent validation at the protein and mRNA level in inde-
pendent shNT and shFLG LSEs derived from biological donors
distinct from those used in the original study to confirm the
findings from the proteomic analysis. The expression profiles of
key representatives from a distinct protein class, such as proteases
(KLK7), immunomodulatory functions (PPIA), and cytoskeletal
interacting proteins (CFL1), were selected based on their low P
value, high donor ratio, and relevance to skin morphology/
disease.
In line with the proteomic results, all 3 proteins were
significantly differentially expressed, as assessed by means of
immunoblotting and densitometric analysis in the independent
LSEs (Fig 5, A and B). Furthermore, both the relative magnitude
and direction of response were preserved: CFL1, 2.16 0.27-fold
(P 5 .03), KLK7, 1.89 6 0.29-fold (P 5 .007), and PPIA,
0.52 6 0.11-fold (P 5 .05; Fig 5, A and B).
FIG 3. Box plot showing differentially expressed proteins after FLG knockdown. Log10 mean protein differ-
ences (shFLG2 shNT) were calculated independently for each biological replicate and collated for statistical
analysis (n 5 10). Displayed proteins were differentially regulated. P <_ .05, 1-sample t test. Values are me-
dians and interquartile ranges.
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difference in CFL1 and PPIA mRNA expression levels between
shNT and shFLG LSEs, as assessed by using probe-based RT-
qPCR assays, underscoring the relevance of a proteomics-based
approach. However, KLK7 mRNA expression was increased in
the shFLG condition, which is consistent with the protein data
(1.2 6 0.06-fold, P 5 .05; Fig 5, C).Replication of FLG knockdown LSE findings in AE
skin
Protein expression analysis was performed on human skin from
healthy control subjects and patients with AE to determine
whether these in vitro findings were relevant to the in vivoAE dis-
ease setting. AE samples were collected from sites of both clini-
cally active eczema (involved skin) and macroscopically normal
skin (uninvolved).
Protein expression of FLG, PPIA, KLK7, and CFL1 was
assessed by using a combination of immunofluorescence imaging
(Fig 6,A) and quantification bymeans of image analysis (Fig 6,B-
E). FLGmutational status of all control subjects and patients with
AE was determined by using next-generation sequencing. All
control subjects reported were FLG wild-type, and 31% of sub-
jects with AE carried FLG mutations (Fig 6, B-E, and see Table
E7 in this article’s Online Repository at www.jacionline.org).
Overall FLG expression was reduced in both uninvolved and
involved AE skin compared with that in healthy control subjects,although significance was only observed at sites of clinically
active disease (0.6 6 0.1-fold, P <_ .05; Fig 6, A and B). FLG
expression was particularly reduced in FLG-heterozygous sub-
jects and almost absent in the FLG double-allele mutant subject
(Fig 6, A and B), and accordingly, a significant correlation be-
tween FLG genotype (number of expressed alleles) and expres-
sion was observed (r5 0.48, P5 .007) across the whole data set.
The protein abundance of PPIA was significantly reduced in
involved AE skin compared with control skin (0.65 6 0.06-fold,
P <_.02), whereas KLK7 expression was significantly increased in
both uninvolved (1.8 6 0.02-fold, P <_ .02) and involved
(1.84 6 0.02-fold, P <_ .009) AE skin. There was a trend toward
correlation between FLG and PPIA expression (r 5 0.31,
P 5 .09) and a significant inverse correlation between FLG and
KLK7 expression (r 5 20.38, P 5 .04). However, in neither
instance did protein expression stratify or correlate according to
FLG mutational status (PPIA: r 5 0.08, P 5 .68; KLK7:
r 5 20.18, P 5 .34; Fig 6, A-D). In contrast, the abundance of
CFL1 was unchanged between normal and AE skin and did not
display any correlation with respective FLG expression
(r 5 20.12, P 5 .51; Fig 6, A).DISCUSSION
In this study we used an in vitro human LSE model to investi-
gate the proteomic changes arising from FLG deficiency per se in
the absence of any confounding systemic inflammation.19
FIG 4. Summary of IPA core functional analysis. Log10 mean protein differences (shFLG 2 shNT) with an
adjusted P value of less than .05 (threshold) were considered significantly differentially expressed and
used as input for IPA. The top 5 ‘‘disease and disorders’’ (A), ‘‘molecular and cellular functions’’ (B), and ‘‘ca-
nonical pathways’’ (C) altered after FLG knockdown are depicted. The orange line depicts the ratio (number
of pathway-relevant proteins in the data set divided by the total number of proteins in the pathway).
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
ELIAS ET AL 7A global proteomics approach and IPA strikingly revealed that
shFLG LSEs displayed a disease profile consistent with inflam-
matory dermatologic disease and an enrichment in proteins asso-
ciated with cellular assembly. Significant functional terms
included ‘‘allergy’’ (increased: ANXA3, CFL1, CTSV, and
KLK7; decreased: FLG and PPIA) and ‘‘differentiation of cells’’
(increased: CFL1, CTSV, and RPL22; decreased: FLG, PPIA, and
VIM), suggesting that our FLG knockdown model displays many
molecular characteristics typical of AE (Fig 4 and see Tables E3-
E6). Similar functional annotations, specifically inflammatory
and extracellular matrix dysregulation, have also been described
in AE transcriptomic data sets,12,13,27 including those from FLG-
null and haplosufficient patients with AE,12,13 reinforcing the util-
ity of our disease model and underscoring the central role of FLG
deficiency in AE pathophysiology.
Carefully controlled protease activity is essential for the
maintenance of epidermal homeostasis and barrier function.28In addition to increased expression of the chymotrypsin-like
serine protease KLK7, expression of the cysteine protease
CTSVand zinc-dependent protease CPA4 was significantly upre-
gulated after FLG knockdown in the LSE model. KLK7 is highly
expressed in skin,29 and its dysregulation has been implicated to
AE pathogenesis; protein expression is increased in both involved
and uninvolved AE skin and in the epidermis of flaky tail
mice.29-31 Furthermore, overexpression of human KLK7 in mu-
rine models causes severe pruritus, increased epidermal thick-
ness, and dermal inflammation.30 Our findings in AE skin are
consistent with these results, demonstrating both increased over-
all epidermal KLK7 expression and ectopic expression within the
lower epidermal compartments compared with those seen in
healthy control skin. Importantly our novel in vitro data demon-
strating increased KLK7 mRNA and protein expression after
FLG knockdown identifies for the first time that KLK7 is tran-
scriptionally regulated, either directly or indirectly downstream
FIG 5. Validation of proteomics findings. Normalized expression levels of CFL1, PPIA, and KLK7 were
determined in shNT and shFLG LSEs generated from independent biological samples. A and B, Represen-
tative immunoblots (n >_ 3; Fig 5, A) and associated densitometric quantification (n >_ 3; Fig 5, B). MW, Mo-
lecular weight. C, TaqMan mRNA expression levels (n 5 8). Scatter plots of log10-transformed data
(means 6 95% CIs).
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expression and an atopic epidermal environment known to be
permissive for protease activation32 has significant implications
for barrier homeostasis. In addition to the perturbations in
epidermal structure, enhanced KLK activity also drives inflam-
mation both directly through IL-1 activation33 and indirectly
through overexpression of thymic stromal lymphopoietin, a
potent inducer and propagator of TH2-polarixed inflammation
downstream of protease activated receptor 2 signaling.34 The
mRNA expression of thymic stromal lymphopoietin is increased
in lesional AE skin,34 flaky tail mice,31 and our LSEs after FLG
knockdown (data not shown). This, combined with our observa-
tion that proteins of known immunomodulatory function (PPIA,
TXN, ANXA3, and LY6D) are significantly perturbed by FLG
knockdown, supports the idea that FLG deficiency can contribute
to AE inflammation independently of immune cells.
PPIA is an ubiquitously expressed immunophilin family
member protein with roles in protein folding, trafficking, and
immune modulation.35 For the first time, we show that PPIA is
downregulated in the context of FLG deficiency and in AE skin
(Figs 3, 5, and 6), suggesting that PPIA might represent a novel
disease mechanism downstream of FLG. Interestingly, PPIA is
the cytoplasmic binding partner of cyclosporine, an effective ther-
apeutic in patients with AE.36 Cyclosporine regulates gene tran-
scription, growth, and differentiation of human keratinocytes,37as well as their production of inflammatory cytokines.38 PPIA
knockout mice experience spontaneous TH2-polarized allergic
disease and an immune profile akin to AE, although no dermatitis
is reported.39 No concurrent reduction in PPIAmRNA expression
was observed in shFLG LSEs (Fig 5,C); the reduction in intracel-
lular protein expression might instead reflect an increase in PPIA
secretion known to be triggered after inflammatory/stress stimuli
in epithelia.35 Extracellular PPIA functions as both a proinflam-
matory stimuli (autocrine/paracrine) and potent chemoattractant
of CD1471 immune cells.35,40 Stress and inflammatory pathways
were overrepresented in our data set after FLG knockdown (Fig
4), and keratinocytes are known to secrete the close family mem-
ber cyclophilin B and to express CD147 cell-surface receptors,41
suggesting that similar regulation of PPIA might occur within the
epidermis. Furthermore, extracellular PPIA and TXN (increased
in shFLGLSEs) have been identified as IgE-reactive self-antigens
in patients with AE,42,43 and therefore their dysregulation might
represent an additional pathogenic mechanism downstream of
FLG.
Finally, cyclophilin members are regulated during epithelial
terminal differentiation,44 suggesting that PPIA dysregulation
downstream of FLG might also have implications for epidermal
barrier structure and function. Keratinocyte differentiation is
associated with extensive keratin and actin remodeling.45 We
also identified significantly differentially expressed proteins
FIG 6. Replication of FLG knockdown LSE findings in AE skin. Representative immunofluorescence images
of normal (FLGwild-type), uninvolved (UN AE), and involved (INV AE) AE skin (n >_ 3). Green staining depicts
FLG, PPIA, KLK7, or CFL1, as indicated. Hoechst 33342 nuclear counterstaining is shown in red (250 mm).
Dashed lines represent the epidermal/dermal boundary. A, Corresponding quantification values are out-
lined in red on the bottom scatter plots. B-E, Scatter plots of the corresponding protein florescence inten-
sities expressed as function of unit area and on a log10 scale (means 6 95% CIs). All subjects are FLG
wild-type unless indicated in orange (FLG heterozygous) or green (FLG homozygous/compound
heterozygous).
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CCT6A, andVIM) as novel targets of FLG loss. CFL1 is an essen-
tial actin-binding protein that regulates cell motility, growth, divi-
sion, and differentiation by controlling actin filament assembly
and disassembly.46 Overexpression of active (unphosphorylated)
CFL1 in LSE models reduces corneocyte compaction, whereas
partial knockdown increased proliferation, supporting a role forCFL1 in keratinocyte homeostasis.47 In our LSE model CFL1
protein but not mRNA expression was significantly increased af-
ter FLG knockdown (Fig 5). Pathways associated with regulation
of the actin cytoskeleton have been reported to be transcription-
ally overrepresented in AE skin,13 and CFL1 mRNA expression
is significantly upregulated in the involved skin of patients with
AE, psoriasis, and lichen planus,48 suggesting that dysregulation
J ALLERGY CLIN IMMUNOL
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mechanism. Interestingly, unlike PPIA and KLK7, the protein
expression pattern of CFL1 in AE skin did not align to the shFLG
LSEmodel, and we observed no increase in CFL1 protein expres-
sion in the patients with AE (Fig E6). The regulation of CFL1 is
complex, involving phosphorylation, inhibitor complexes, and
cooperation with other actin-binding proteins46; understanding
its role in patients with AE will require further investigation.
Further IPA analysis significantly associated dysregulation of
eIF2 (RPL22, RPL4, RPS27, and RPS5), eIF4 (RPS27 and
RPS5), and mTOR (RPS27 and RPS5) signaling with FLG
knockdown. Collectively, these pathways cooperate to regulate
transcriptional and translational initiation in response to a wide
variety of environmental stress stimuli, including infection.49,50
Patients with AE have an increased susceptibility to both dissem-
inated viral (eczema herpeticum) and bacterial skin infections,51
and the risk of both is increased in FLG-deficient subjects.52
Consistent with this, stress responses, namely type 1 interferon–
mediated anti-pathogenic deference, are overrepresented in the
transcriptome of FLG-null and haplosufficient patients with
AE,12 and furthermore, type 1 interferon expression is increased
in patients with eczema herpeticum.53 Type 1 interferons are
secreted after viral54 or bacterial55 infection and mediate both
immunomodulatory responses and local cell-cycle regulation in
part through activation of eIF2,56 mTOR, and downstream p70-
S6K/eIF4 signaling.57 For the first time, our in vitro data suggest
that the exaggerated but ineffective upregulation of type 1 inter-
feron–mediated defense observed in patients with AE12 might
reflect an inherent defect downstream of FLG rather than/in addi-
tion to a deregulated response to pathogen exposure.12,53 There-
fore dysregulation of these pathways as a result of inherited or
acquired FLG deficiencymight contribute to the propensity of pa-
tients with AE to have bacterial and viral skin infections.
Overall, our data reinforce that loss of FLG is itself an
important pathogenic factor in patients with AE, driving the
development and exacerbation of barrier and immune dysfunc-
tion. Importantly, we have shown that loss of FLG alone in the
absence of any systemic immune signals can disrupt epidermal
homeostasis resulting in proteomic changes relevant to AE. Our
data are consistent with the so-called ‘‘outside-to-inside’’ disease
hypothesis and places FLG deficiency firmly upstream of prote-
ase, innate inflammatory, and cytoskeletal pathway dysregula-
tion. The observed protein changes in AE skin occurred to a
similar degree in FLG-depleted, FLG wild-type, and single- and
double-allele mutated subjects, suggesting that the mechanism
of FLG reduction (whether through genotype, cytokine effects,
or a combination thereof) might not be important.
For the first time, we have identified 17 proteins that are
significantly differentially expressed in the absence of FLG,
including KLK7, PPIA, and CFL1. Confirmation of these results
in independent LSE cultures validates the proteomics methodol-
ogies, interpretation and the biological reproducibility of our
identified targets. Replication of PPIA and KLK7 expression
profiles in skin biopsy specimens from patients with AE further
underscores the utility of our disease model. To the best of our
knowledge, this is the first study to implicate loss of PPIA
resulting from FLG deficiency to AE pathogenesis and also to
show that the known increase in KLK7 expression observed in AE
skin can occur as a consequence of FLG loss. Finally, our pathway
analysis suggests a possible role of FLG deficiency in regulating
cell stress, including mTOR, eIF4, and eIF2 signaling, which isbroadly consistent with RNA sequencing analysis of uninvolved
FLG-deficient AE skin.12 Lack of correlation between the protein
and mRNA expression profiles of CFL1 and PPIA emphasize the
value of proteomic studies. Complementary transcriptomic
studies will provide further understanding of the signaling mech-
anisms upstream of our observations. To this end, development of
robust bioinformatic platforms for the integration of transcrip-
tomic and proteomic data sets will be hugely valuable.
We thank the BBSRC, Stiefel (GlaxoSmithKline), and the Technology
Strategy Board for funding this research.We also thank Dr Alex Laude and Dr
Trevor Booth at the Newcastle University Bio-imaging unit for help and
advice on confocal imaging and thanks Carole Todd for her expert technical
support. We also thank Professor Olaf Heidenreich, Northern Institute for
Cancer Research, Newcastle University, for providing the second-generation
packaging and envelope vectors and for his assistance in establishing the
lentiviral transduction methodology. We thank the Departments of Derma-
tology, Paediatric Surgery, Plastic Surgery, andUrology, Newcastle upon Tyne
Hospitals, NHS Foundation Trust, for their help in recruiting patients.
Key messages
d Loss of FLG in the absence of inflammation is sufficient to
induce molecular changes characteristic of AE, including
inflammatory, proteolytic, and cytoskeletal dysregulation.
d The immunophilin PPIA is a novel protein decreased in
FLG-deficient LSEs and clinically active AE skin.
d The characteristic upregulation of KLK7 expression in
patients with AE occurs downstream of FLG loss.
d Disconnect occurs between the epidermal proteome and
transcriptome, highlighting the importance of proteomic
studies for the identification of disease mechanisms.REFERENCES
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